Research Center for Macromolecules and Biomaterials, National Institute for Materials Science (NIMS), Tsukuba, Ibaraki, Japan.
Bioanalysis Unit, Research Network and Facility Services Division, National Institute for Materials Science (NIMS), Tsukuba, Ibaraki, Japan.
Front Immunol. 2024 Jan 8;14:1328379. doi: 10.3389/fimmu.2023.1328379. eCollection 2023.
Considering the diversity of tumors, it is of great significance to develop a simple, effective, and low-cost method to prepare personalized cancer vaccines.
In this study, a facile one-pot synthetic route was developed to prepare cancer vaccines using model antigen or autologous tumor antigens based on the coordination interaction between Fe ions and endogenous fumarate ligands.
Herein, Fe-based metal organic framework can effectively encapsulate tumor antigens with high loading efficiency more than 80%, and act as both delivery system and adjuvants for tumor antigens. By adjusting the synthesis parameters, the obtained cancer vaccines are easily tailored from microscale rod-like morphology with lengths of about 0.8 μm (OVA-ML) to nanoscale morphology with sizes of about 50~80 nm (OVA-MS). When cocultured with antigen-presenting cells, nanoscale cancer vaccines more effectively enhance antigen uptake and Th1 cytokine secretion than microscale ones. Nanoscale cancer vaccines (OVA-MS, dLLC-MS) more effectively enhance lymph node targeting and cross-presentation of tumor antigens, mount antitumor immunity, and inhibit the growth of established tumor in tumor-bearing mice, compared with microscale cancer vaccines (OVA-ML, dLLC-ML) and free tumor antigens.
Our work paves the ways for a facile, rapid, and low-cost preparation approach for personalized cancer vaccines.
考虑到肿瘤的多样性，开发一种简单、有效且低成本的方法来制备个性化癌症疫苗具有重要意义。
在这项研究中，我们开发了一种简便的一锅合成方法，基于 Fe 离子与内源性富马酸配体之间的配位相互作用，使用模型抗原或自体肿瘤抗原制备癌症疫苗。
在此，Fe 基金属有机骨架可以有效地包封具有 80%以上高负载效率的肿瘤抗原，并且可以作为肿瘤抗原的递送系统和佐剂。通过调整合成参数，所得到的癌症疫苗可以很容易地从微尺度的棒状形貌（OVA-ML）调整为纳米尺度的形貌（OVA-MS），长度约为 0.8μm。当与抗原呈递细胞共培养时，纳米级癌症疫苗比微尺度癌症疫苗更有效地增强抗原摄取和 Th1 细胞因子分泌。与微尺度癌症疫苗（OVA-ML，dLLC-ML）和游离肿瘤抗原相比，纳米级癌症疫苗（OVA-MS，dLLC-MS）更有效地增强了肿瘤抗原在淋巴结中的靶向和交叉呈递，引发抗肿瘤免疫，并抑制荷瘤小鼠中已建立肿瘤的生长。
我们的工作为制备个性化癌症疫苗开辟了简便、快速且低成本的方法。
